noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Shentel - Shenandoah[...]

Statement of Changes in Beneficial Ownership (Form 4)
DASNY - Dormitory Authority of the[...]

$10.2 Million in NY BRICKS Awards Strengthen Community Centers Across[...]
Krystal Biotech Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Healthcare

Interpace Biosciences Inc.

01/09/2025 | Press release | Distributed by Public on 01/09/2025 17:13

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Interpace Biosciences Inc. published this content on January 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 09, 2025 at 23:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]